Jasper Therapeutics
JSPR
22 hedge funds and large institutions have $9.57M invested in Jasper Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.08% less ownership
Funds ownership: 5.54% → 5.46% (-0.08%)
4% less funds holding
Funds holding: 23 → 22 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
39% less capital invested
Capital invested by funds: $15.7M → $9.57M (-$6.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
Fernwood Investment Management
Quincy,
Massachusetts
|
+$106K |
| 2 |
Renaissance Technologies
New York
|
+$24.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$22.1K |
| 5 |
Millennium Management
New York
|
+$19.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$316K |
| 2 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
-$3.88K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$669 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$562 |
JSPR Hedge Fund Activity: Q4 2022 in Review
22 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2022, worth a combined $9.57M — down 39% from $15.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of JSPR and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 6 added.
The largest buyer was Fernwood Investment Management, adding an estimated $106K. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $316K sold.
- 22 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2022, down from 23 in Q3 2022.
- Funds reported $9.57M of Jasper Therapeutics stock for Q4 2022, down 39% quarter-over-quarter.
- 3 funds opened new Jasper Therapeutics positions in Q4 2022 and 4 closed out, a net change of -1 holder.
- The largest Jasper Therapeutics buyer in Q4 2022 was Fernwood Investment Management, an estimated $106K added.
- The largest Jasper Therapeutics seller in Q4 2022 was Sectoral Asset Management, an estimated $316K sold.
Based on aggregated 13F filings for Q4 2022.